EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ASCO 2020 non-small lung cancer (NSCLC) personal highlights

Lena Horvath, Andreas Pircher iD

memo - Magazine of European Medical Oncology · 2021-03 · 14 (1) · 66-69

DOI: 10.1007/s12254-020-00673-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift memo - Magazine of European Medical Oncology, online erschienen am 13.01.2021. Verfasst von Lena Horvath und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Internal Medicine V, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Innsbruck and Medical University of Innsbruck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering developments in early and advanced-stage NSCLC. Until recently early stage NSCLC patients were treated independently of their genetic profile. Now the ADAURA study proved that postoperative osimertinib significantly prolongs disease-free survival compared to standard chemotherapy in EGFR-mutated NSCLC , underlining the high efficacy of targeted therapies in early stages. In advanced-stage disease, of course immunotherapy (IO) was at the center of attention. Final analysis of KEYNOTE-189 (pembrolizumab plus chemotherapy versus chemotherapy alone) and 3‑year update of CheckMate 227 (nivolumab plus ipilimumab versus standard chemotherapy) proved the long-term overall survival benefit of IO combinations in the first-line setting independent of PD-L1 status. The innovative CheckMate 9LA study demonstrated rapid disease control with limited-course chemotherapy plus IO doublet, while sparing chemotoxicity and may soon become a new clinical treatment choice. Moreover, the phase II CITYSCAPE trial presented significant response rates of the TIGIT-inhibitor tiragolumab plus atezolizumab in PD-L1 positive NSCLC. For HER2-mutated patients a highly effective drug conjugate trastuzumab deruxtecan was presented in a phase II study, extending targeted agents in genetically driven NSCLC. Altogether, ASCO 2020 could excite with inspiring new data for an optimized and more individualized NSCLC treatment regimen, contributing to a better outcome for both early and late-stage diseased patients and continuing to decrease lung cancer mortality.

Schlagwörter

Stichwörter der Autor:innen

AtezolizumabEGFRIpilimumabNivolumabOsimertinibTiragolumabTrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Internal Medicine V, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.

ORCID-Profile: Andreas Pircher

Förderung

  • University of Innsbruck and Medical University of Innsbruck

Zitieren

APA

Horvath, L., & Pircher, A. (2021). ASCO 2020 non-small lung cancer (NSCLC) personal highlights. memo - Magazine of European Medical Oncology, 14(1), 66-69. https://doi.org/10.1007/s12254-020-00673-2

Vancouver

Horvath L, Pircher A. ASCO 2020 non-small lung cancer (NSCLC) personal highlights. memo - Magazine of European Medical Oncology. 2021;14(1):66-69. doi:10.1007/s12254-020-00673-2

BibTeX
@article{Horvath2021,
  author = {Horvath, Lena and Pircher, Andreas},
  title = {ASCO 2020 non-small lung cancer (NSCLC) personal highlights},
  journal = {memo - Magazine of European Medical Oncology},
  year = {2021},
  volume = {14},
  number = {1},
  pages = {66--69},
  doi = {10.1007/s12254-020-00673-2}
}
Kostenlos starten →